美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Generate Biomedicines

12.61

+0.11000.88%

盤後：12.610.00000.00%17:23 EDT

成交量：29.14萬

成交額：367.22萬

市值：16.07億

市盈率：-6.44

高：12.88

開：12.60

低：12.35

收：12.50

52周最高：15.32

52周最低：11.00

股本：1.27億

流通股本：2,500.00萬

量比：0.85

換手率：1.17%

股息：- -

股息率：- -

每股收益(TTM):-1.9580

每股收益(LYR):-4.9816

淨資產收益率：-81.72%

總資產收益率：-34.63%

市淨率：-2.61

市盈率(LYR):-2.53

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

BUZZ-摩根士丹利看好 Generate Biomedicines，稱主要哮喘藥物實力強勁

摩根士丹利首予Generate Biomedicines增持評級目標價20美元

Piper Sandler首予Generate Biomedicines增持評級目標價24美元

異動解讀 | 市場波動引發投資者謹慎，Generate Biomedicines盤中大跌9.38%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GENB"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":12.61,"timestamp":1776369600000,"preClose":12.5,"halted":0,"volume":291397,"hourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.61,"latestTime":"17:23 EDT","volume":610,"amount":7691.9,"timestamp":1776374616462,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008799999999999954,"floatShares":25000000,"shares":127450200,"eps":-1.958,"marketStatus":"已收盤","change":0.11,"latestTime":"04-16 16:00:00 EDT","open":12.6,"high":12.88,"low":12.35,"amount":3672204.808996,"amplitude":0.0424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.958,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":5,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":12.5,"preHourTrading":{"tag":"盘前","latestPrice":12.51,"preClose":12.5,"latestTime":"09:28 EDT","volume":190,"amount":2424.00993,"timestamp":1776346119624,"change":0.01,"changeRate":0.0008,"amplitude":0.036},"postHourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.61,"latestTime":"17:23 EDT","volume":610,"amount":7691.9,"timestamp":1776374616462,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.853717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":25000000,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.853717,"shares":127450200,"dividePrice":0,"high":12.88,"amplitude":0.0424,"preClose":12.5,"low":12.35,"week52Low":11,"pbRate":"-2.61","psRate":"50.39","week52High":15.32,"institutionHeld":0,"latestPrice":12.61,"eps":-1.958,"divideRate":0,"volume":291397,"delay":0,"ttmEps":-1.958,"open":12.6,"prevYearClose":16,"prevWeekClose":11.41,"prevMonthClose":12.5,"prevQuarterClose":12.5,"fiveDayClose":11.53,"twentyDayClose":11.81,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1776139200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-04-15","current":-6.440245,"percent":0.15625,"low":-10.037721,"twenty":-8.048998,"median":-7.660036,"eighty":-7.414112,"high":-7.032678,"avg":-7.763645,"sd":0.548051,"marketCap":1642833090},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-15","current":-8.086639,"twenty":-8.048998,"median":-7.660036,"eighty":-7.414112,"marketCap":1642833090}],"updateTime":1776397228341},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622006871","title":"BUZZ-摩根士丹利看好 Generate Biomedicines，稱主要哮喘藥物實力強勁","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006871","media":"路透中文","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006871?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461151,"startTime":"0","endTime":"0","summary":"3月25日 - ** 随着研究静默期的结束，摩根士丹利给予药物开发商 Generate Biomedicines GENB.O \"增持 \"评级** 该公司上月底在纳斯达克上市后，在开盘时获得了近19.1亿美元的估值 。** 券商称，\"我们认为 GENB 的主要资产 GB-0895 与生产重磅药物的商业基准相比，具有同类最佳的潜力\"。** GB-0895 是 GENB 公司治疗严重哮喘的主导产品，目前正在进行后期试验。** 高盛、摩根士丹利、派珀桑德勒、古根海姆证券和坎特是 GENB 公司此次发行的承销商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D1SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4127","GENB","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170560375","title":"摩根士丹利首予Generate Biomedicines增持評級 目標價20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170560375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170560375?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:45","pubTimestamp":1774356311,"startTime":"0","endTime":"0","summary":"摩根士丹利宣布，首次覆盖生物医药公司Generate Biomedicines，并给予“增持”评级。该机构同时设定了20美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184653688","title":"Piper Sandler首予Generate Biomedicines增持評級 目標價24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184653688","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184653688?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 15:44","pubTimestamp":1774338251,"startTime":"0","endTime":"0","summary":"Piper Sandler近日宣布，正式启动对生物医药公司Generate Biomedicines的研究覆盖，并给予其\"增持\"评级。该机构同时设定了24美元的目标股价，显示出对该公司未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165464916","title":"異動解讀 | 市場波動引發投資者謹慎，Generate Biomedicines盤中大跌9.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165464916","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165464916?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 02:10","pubTimestamp":1772215808,"startTime":"0","endTime":"0","summary":"Generate Biomedicines（GENB）今日盘中股价大跌9.38%，引起了市场的广泛关注。消息面上，由于挥之不去的市场波动使投资者对新上市企业保持谨慎，导致该股在首次上市时股价承压。根据相关报道，市场整体波动性使得投资者风险偏好降低，对新上市的股票采取更为保守的态度，从而影响了Generate Biomedicines的股价表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GENB\",params:#limit:6,delay:false,,,undefined,":[]}}